Evaluation of the effect of 5% hypertonic saline nebulization on inflammatory factors and recovery in patients with severe pneumonia caused by covid 19

Evaluation of the Efficacy of nebulized 5% hypertonic saline on inflammatory factors and recovery of severe pneumonia in patients with Covid-19 hospitalized in intensive care units

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120216009045N4

Enrollment

Registered

2021-12-01

Start date

2021-12-11

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of 5% hypertonic saline on blood levels of inflammatory factors in patients with severe pneumonia caused by covid 19. Other viral pneumonia

Interventions

Intervention 1: Intervention group: Patients receiving 10 ml, 5% hypertonic saline nebulization during ICU admission. Intervention 2: Control group: Patients who receive 10 ml of distilled water throu

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient with Covid-19 coronavirus (confirmation of diagnosis by positive PCR test) Severe pneumonia due to COVID-19 Age 70 - 18 years Conscious consent of the patient or her guardian in cases that the patient is not conscious.

Exclusion criteria

Exclusion criteria: Receiving interleukin production inhibitors such as Octemra Patients with a history of HIV + or any history of immunodeficiency Patient with active bacterial pneumonia Primary or metastatic lung cancer History of any cancer or malignancy Chronic lung diseases include: pulmonary fibrosis, bronchiectasis, asthma smoking Previous thoracic and lung surgery Patients with hypernatremia Intubated patients

Design outcomes

Primary

Measure	Time frame
Interleukin 6. Timepoint: While hospitalized in the ICU for 5 days, before and after of intervention. Method of measurement: Samples containing the biomarkers are transferred to a reference laboratory in an EDTA-containing test tube, and centrifuged at 3,000 rpm for 15 minutes. The resulting plasma for measuring IL-6, TNF-a markers is stored by the researcher at minus 80 ° C. Quantitative determination is done by the quantitative sandwich enzyme immunoassay method by Bendermed commercial kits.;Measurement of serum TNF_a before and after the intervention. Timepoint: During 5 days of admission in the ICU. Method of measurement: Samples containing the biomarkers are transferred to a reference laboratory in an EDTA-containing test tube, and centrifuged at 3,000 rpm for 15 minutes. The resulting plasma for measuring IL-6, TNF-a markers is stored by the researcher at minus 80 ° C. Quantitative determination is done by the quantitative sandwich enzyme immunoassay method by Bendermed commercial kits.	—

Measure

Time frame

Interleukin 6. Timepoint: While hospitalized in the ICU for 5 days, before and after of intervention. Method of measurement: Samples containing the biomarkers are transferred to a reference laboratory in an EDTA-containing test tube, and centrifuged at 3,000 rpm for 15 minutes. The resulting plasma for measuring IL-6, TNF-a markers is stored by the researcher at minus 80 ° C. Quantitative determination is done by the quantitative sandwich enzyme immunoassay method by Bendermed commercial kits.;Measurement of serum TNF_a before and after the intervention. Timepoint: During 5 days of admission in the ICU. Method of measurement: Samples containing the biomarkers are transferred to a reference laboratory in an EDTA-containing test tube, and centrifuged at 3,000 rpm for 15 minutes. The resulting plasma for measuring IL-6, TNF-a markers is stored by the researcher at minus 80 ° C. Quantitative determination is done by the quantitative sandwich enzyme immunoassay method by Bendermed commercial kits.

—

Secondary

Measure	Time frame
Mortality rate in two groups. Timepoint: During admission in the ICU. Method of measurement: Status of patient leaving ICU: alive or dead.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Taghi Beigmohammadi

Tehran University of Medical Sciences

mbage46@gmail.com+98 21 6119 2511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026